GARDEN (Global Hematological Rare Diseases Alliance)/LinkedIn
May 23, 2026, 14:42
How Should Evidence Be Interpreted in Modern Hemophilia Care? – GARDEN
GARDEN (Global Hematological Rare Diseases Alliance) shared a post on LinkedIn:
“How should evidence be interpreted in modern hemophilia care?
In this new contribution from the GARDEN editorial series, Prof. Cedric Hermans explores the methodological debate behind international hemophilia guidelines, examining the balance between randomized clinical trials, real-world evidence, and patient-centered decision-making.
A critical reflection on how evidence shapes clinical practice, access to care, and the future of hemophilia management.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 16:51Suzan Nakasendwa: A Growing Stroke Challenge in Uganda
-
Oct 20, 2026, 16:38Steve Moon: How Does Smoking Cessation Duration Affect Ischemic Stroke Risk
-
Oct 20, 2026, 16:25Cedrice Mentor: Reducing Platelet Wastage Through Cold Storage
-
Oct 20, 2026, 16:09Thirunavukkarasu Angappan: Can a Purified Fibrinogen Concentrate Replace Cryoprecipitate
-
Oct 20, 2026, 16:01Kalyan Roy: Platelet Conservation Through Evidence-Based Transfusion Practice
-
Oct 20, 2026, 15:28Stacy E. Croteau: 33 Countries, One Mission – Better Bleeding Disorder Care
-
Oct 20, 2026, 15:19Teresa Barnes: What Does a Pulmonary Embolism Mean for Jalen Hurts?
-
Oct 20, 2026, 15:04Laura S.: Could Speaking Up Prevent Maternal Deaths from Thrombosis?
-
Oct 20, 2026, 14:44Pete Stibbs: VTE in Professional Athletes – When Fitness Is Not Enough